Pembrolizumab
Merck
[' ave ', 'sorafenib', 'pazopanib', 'onc 201', 'rcc,(-irccs),(-srcc),(-urcc)', 'renal,(-adrenal)', 'rapport', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
 provides some very compelling arguments for sabr for oligometastatic renal cancer. likely very underutilized albeit best data is relatively recent #gu23 
Urologist & Director of GU Oncology, Peter MacCallum Cancer Centre | Professor, University of Melbourne | Podcasting at GU Cast. Views my own. RT = endorsement